Project Grant R01AI183642
Award Date
12/20/24
Completion Date
11/30/29
Dollars Obligated
$950K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98105, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $404,539 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Rochester General Hospital in Rochester, NY. The grant, awarded on November 18, 2024, supports the development and evaluation of a novel lipoprotein fusion vaccine against nontypeable Haemophilus influenzae (NTHI) infections. The research aims to enhance antibody and T-cell mediated immunity against NTHI through...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $711,993 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on June 11, 2025. The grant supports research to understand the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis, immunity, and persistence in people living with HIV. Specifically, the project will assess how MTB disease impacts the HIV-1 immune response,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,071 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a universal transmission blocking vaccine against malaria. The goal is to create a vaccine targeting conserved mosquito-stage antigens that can prevent infection across multiple Plasmodium species that cause malaria. Key aspects...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to evaluate the safety, immunogenicity, and efficacy of an attenuated Mycobacterium tuberculosis (MTB) vaccine candidate in the setting of HIV co-infection. The $905,998 award to the Texas Biomedical Research Institute aims to directly test the hypothesis that the SIGH-based attenuated MTB vaccine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $813,160 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The goal is to create vaccines that provide effective immune protection against malaria infection and reduce disease transmission. The project will evaluate protective efficacy of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $516,175 Project Grant under CFDA 93.855, Allergy and Infectious Diseases Research, to Seattle Children's Hospital/Seattle Children's Research Institute. The grant, effective June 23, 2025 through May 31, 2027, will fund research to evaluate the impact of pre-existing humoral immunity on hepatocyte death in the context of malaria infection. The research aims to understand how non-neutralizing antibodies that bind...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $185,280 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas A&M University System Health Science Center to study how the Mycobacterium tuberculosis (MTB) secreted protein Rv1075c hijacks host histone methyltransferases to promote infection. The key objectives are to define how histone methylation changes at innate immune genes during MTB infection, and investigate how...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
This three-year, $18.13 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at the University of Washington and five sub-awardee institutions to develop broadly protective coronavirus vaccines. Under the Allergy and Infectious Diseases Research program, the grantee and sub-awardees will pursue three outputs: tools to study coronaviruses, antibodies for treatment, and vaccine candidates. They will generate reverse...